Eli Lilly has taken the unprecedented step of temporarily halting shipments of Mounjaro (tirzepatide) to the UK market, ahead of an expected price adjustment. The move comes amid growing concerns that customers and healthcare providers might engage in stockpiling, attempting to purchase larger quantities before the medication’s cost increases. This proactive measure highlights the company’s attempt to manage supply chain stability and ensure equitable distribution of the diabetes and obesity treatment during this volatile period.

Sources indicate that Lilly’s decision was influenced by several factors:

  • Preventing sudden inventory surges that could disrupt supply for other patients.
  • Aligning pricing structures to reflect the drug’s clinical value and reimbursement negotiations.
  • Ensuring a smoother transition for healthcare providers adapting…